Evidence map›Paper›PMID 40558276›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Germline TP53 p.R337H and XAF1 p.E134* Variants: Prevalence in Paraguay and Comparison with Rates in Brazilian State of Paraná and Previous Findings at the Paraguayan-Brazilian Border.

Edith Falcon-de Legal, Marta Ascurra, Rosa Vega-Paredes, Elis Sade, Magna Monteiro, Mariana Paraízo, Magali Colman, Angeles Gutierrez Florentin, Cesar Ojeda, Horacio Legal-Ayala and 1 more

Abstract readComparative Study
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Edith Falcon-de LegalLaboratorio de Bio y Materiales, NIDTEC-Núcleo de Investigación y Desarrollo Tecnológico, Facultad Politécnica, Universidad Nacional de Asunción, Campus UNA, San Lorenzo 111421, Paraguay.ORCID 0009-0004-8045-8202
Marta AscurraPrograma de Prevención de la Fibrosis Quística y del Retardo Mental, Centro de Salud No. 9, Ministerio de Salud Pública y Bienestar Social, Asunción 001222, Paraguay.
Rosa Vega-ParedesDepartamento de Bioquímica Clínica, Universidad del Norte, Asunción 001218, Paraguay.
Elis SadeHospital de Clinicas, Universidade Federal do Paraná, Curitiba 80060-000, Brazil.
Magna MonteiroLaboratorio de Bio y Materiales, NIDTEC-Núcleo de Investigación y Desarrollo Tecnológico, Facultad Politécnica, Universidad Nacional de Asunción, Campus UNA, San Lorenzo 111421, Paraguay.ORCID 0000-0002-5078-7214
Mariana ParaízoInstituto de Pesquisa Pelé Pequeno Príncipe, Curitiba 80250-060, Brazil.
Magali ColmanCEBIOTEC-Centro de Investigación en Biotecnología e Informática, Asunción 001226, Paraguay.
Angeles Gutierrez FlorentinCEBIOTEC-Centro de Investigación en Biotecnología e Informática, Asunción 001226, Paraguay.
Cesar OjedaCEBIOTEC-Centro de Investigación en Biotecnología e Informática, Asunción 001226, Paraguay.
Horacio Legal-AyalaNIDTEC-Núcleo de Investigación y Desarrollo Tecnológico, Facultad Politécnica, Universidad Nacional de Asunción, Campus UNA, San Lorenzo 111421, Paraguay.ORCID 0000-0002-1790-2559
Andreas RiesNIDTEC-Núcleo de Investigación y Desarrollo Tecnológico, Facultad Politécnica, Universidad Nacional de Asunción, Campus UNA, San Lorenzo 111421, Paraguay.ORCID 0000-0002-2976-7964

Funding

Consejo Nacional de Ciencia y Tecnología N/ACoordenação de Aperfeicoamento de Pessoal de Nível Superior N/A
6 · The paper itself

Abstract

Adrenal cortex carcinoma (ACC) in children is a rare tumor that is probably of multifactorial origin and is mainly associated with genetic and environmental alterations. In the south and part of the southeast of Brazil, as well as in the Paraguayan region bordering the Brazilian State of Paraná, ACC prevalence is higher than in any other country, which is associated with the high prevalence of the TP53 p.R337H variant in Paraná (0.30%), Santa Catarina (0.249%), cities around Campinas-SP (0.21%), and the Paraguayan cities on the border with Paraná (0.05%). Recent research suggests that the co-segregation of XAF1-E134* and TP53-R337H mutations leads to a more aggressive cancer phenotype than TP53-R337H alone. Breast cancer may be mildly influenced by co-segregation with XAF1 p.E134*, and this variant can also confer risk for sarcoma.

objectivesThe objectives of this study were to (1) estimate the prevalence of the germline TP53 p.R337H and XAF1 p.E134* variants in Paraguay (excluding cities on the border with Paraná State, Brazil) and (2) estimate whether the ethnic origin of TP53 p.R337H carriers in Paraguay is similar to that of ethnic groups in Paraná (possible Portuguese/Spanish origin). MATERIALS AND

methodsDNA tests for the identification of TP53 p.R337H were carried out from 2016 to 2019 at the Bio-Materials Laboratory of Facultad Politecnica, UNA, and at the Research Center in Biotechnology and Informatics (CEBIOTEC), Asunción, Paraguay. Polymerase chain reaction followed by restriction enzyme digestion (PCR-RFLP) was used to identify TP53 p.R337H, and real-time PCR (RT-PCR) was employed for XAF1 p.E134*. Peripheral blood samples from 40,000 Paraguayan newborns (NBs) were used for the TP53 p.R337H tests. The XAF1 p.E134* tests (RT-PCR) were performed on samples from 2000 Paraguayan newborns at the Pelé Pequeno Principe Research Institute, Curitiba, PR, Brazil.

resultsThe TP53 p.R337H variant was not found in any of the 14 Paraguayan departments investigated. A total of 12 of the 2000 Paraguayan NBs were positive for one XAF1 p.E134* allele.

conclusionsThe hypothesis of Spanish immigrants carrying p.R337H to Paraguay was disproved. TP53 p.R337H neonatal testing in Paraguay is not recommended, except when there are families with Brazilian ancestry presenting cancer cases. Additional epidemiological studies are required to determine the likelihood of the identified prevalence of the XAF1 p.E134* allele (1/153) in NBs from Paraguay without TP53 p.R337H to present cancer risk. This study complements the first national initiative for the DNA screening of newborns aimed at mapping the TP53 p.R337H and XAF1 p.E134* variants in Paraguay (based on the regions of residence of the newborns).

Indexed as

Germ-Line MutationNeoplasm ProteinsTumor Suppressor Protein p53BrazilChildFemaleHumansMaleParaguayPrevalenceNeoplasm ProteinsTP53 protein, humanTumor Suppressor Protein p53adrenal glandcancerLi–Fraumeni syndromeTP53 p.R337H variantXAF1 p.E134* variant

Identifiers

PMID40558276
PMCPMC12191968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.